Expression of apoptotic regulatory molecules in renal cell carcinoma: Elevated expression of Fas ligand

Immunology and Cell Biology

Volumn 77, Issue 1, 1999, Pages 11-18

  Olive, Colleen ^a,b   Cheung, Catherine ^a   Nicol, David ^a   Falk, Michael C ^a  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

bcl 2; Fas; Fas ligand; Immune escape; Renal cell carcinoma

Indexed keywords

COMPLEMENTARY DNA; FAS LIGAND; PROTEIN BCL 2; RNA;

ADULT; AGED; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; MALE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR ASSOCIATED LEUKOCYTE;

ADULT; AGED; ANTIGENS, CD95; BASE SEQUENCE; CARCINOMA, RENAL CELL; CASE-CONTROL STUDIES; DNA PRIMERS; FAS LIGAND PROTEIN; FEMALE; GENE EXPRESSION; GENES, BCL-2; HUMANS; KIDNEY NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; RNA, MESSENGER; RNA, NEOPLASM; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0032989519     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1711.1999.00791.x     Document Type: Article

References (52)

1. 1 Mancilla-Jimenez R. Papillary renal cell carcinoma: A clinical, radiologic and pathologic study of 34 cases. Cancer 1976; 38: 2466-8.
2. 2 Topalian SL, Solomon D, Rosenberg SA. Tumour specific cytolysis by lymphocytes infiltrating human melanomas. J. Immunol. 1989; 142: 3714-25.
3. 3 Ioannides CG, Fisk B, Pollack MS, Frazier ML, Taylor-Wharton J, Freedman RS. Cytotoxic T-cell clones isolated from ovarian tumour infiltrating lymphocytes recognise common determinants on non-ovarian tumour clones. Scand. J. Immunol. 1993; 37: 413-24.
4. 4 Crannage KE, Rogers K, Jacob G et al. Factors influencing the establishment of tumour-infiltrating lymphocyte cultures from human breast and colon carcinoma. Eur. J. Cancer 1991; 27: 149-54.
5. 5 Ghosh AK, Moore M. Tumour-infiltrating lymphocytes in cervical carcinoma. Eur. J. Cancer 1992; 28A: 1910-16.
6. 6 Hald J, Rasmussen M, Claesson MH. Tumour-infiltrating lymphocytes mediate lysis of autologous squamous cell carcinomas of the head and neck. Cancer Immunol. Immunother. 1995; 41: 243-50.
7. 7 Finke JH, Zea AH, Stanley J et al. Loss of T-cell-receptor zetachain, p561ck in T-cell-infiltrating human renal-cell carcinoma. Cancer Res. 1993; 53: 5613-16.
8. 8 Alexander JP, Kudoh S, Melsop KA et al. T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors. Cancer Res. 1993; 53: 1380-7.
9. 9 Brouwenstijn N, Gaugler B, Kruse KM et al. Renal-cell carcinoma-specific lysis by cytotoxic T-lymphocyte clones isolated from peripheral blood lymphocytes and tumor-infiltrating lymphocytes. Int. J. Cancer 1996; 68: 177-82.
10. 10 Caignard A, Guillard M, Gaudin C, Escudier B, Triebel F, Dietrich P-Y. In situ demonstration of renal-cell-carcinoma-specific T-cell clones. Int. J. Cancer 1996; 66: 564-70.
11. 11 Choudhary A, Davodeau F, Moreau A, Peyrat M-A, Bonneville M, Jotereau F. Selective lysis of autologous tumor cells by recurrent γδ tumor-infiltrating lymphocytes from renal carcinoma. J. Immunol. 1995; 154: 3932-40.
12. 12 Finke JH, Rayman P, Edinger M et al. Characterization of a human renal cell carcinoma specific cytotoxic CD8+ T cell line. J. Immunother. 1992; 11: 1-11.
13. 13 Koo AS, Tso CL, Shimabukuro T, Peyret C, Dekernion JB, Belldegrun A. Autologous tumor-specific cytotoxicity of tumor-infiltrating lymphocytes derived from human renal cell carcinoma. J. Immunother. 1991; 10: 347-54.
14. 14 Mitropoulos D, Kooi S, Rodriguez-Villanueva J, Platsoucas CD. Characterization of fresh (uncultured) tumour-infiltrating lymphocytes (TIL) and TIL-derived T cell lines from patients with renal cell carcinoma. Clin. Exp. Immunol. 1994; 97: 321-7.
15. 15 Schendel DJ, Gansbacher B, Oberneder R et al. Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes. I. HLA-A2-restricted recognition of autologous and allogeneic tumor lines. J. Immunol. 1993; 151: 4209-20.
16. 16 Pierce WC, Belldegrun A, Figlin RA. Cellular therapy: Scientific rationale and clinical results in the treatment of metastatic renal-cell carcinoma. Semin. Oncol. 1995; 22: 74-80.
17. 17 Tada T, Ohzeki S, Utsumi K et al. Transforming growth factor-β-induced inhibition of T cell function: Susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in tumor bearing state. J. Immunol. 1991; 146: 1077-82.
18. 18 Jakobsen MK, Restifo NP, Cohe PA et al. Defective major histocompatibility complex class I expression in a sarcomatoid renal cell carcinoma cell line. J. Immunother. Emphasis Tumor Immunol. 1995; 17: 222-8.
19. + T cells by B7-transfected melanoma cells. Science 1993; 259: 368-70.
20. 20 Hahne M, Rimoldi D, Schroter M et al. Melanoma cell expression of Fas (APO-1/CD95) ligand: Implications for tumor immune escape. Science 1996; 274: 1363-6.
21. 21 Nagata S. Fas ligand and immune evasion. Nature Med. 1996; 2: 1306-7.
22. 22 O'Connell J, O'Sullivan GC, Collins JK, Shanahan F. The Fas counter attack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med. 1996; 184: 1075-82.
23. 23 Shiraki K, Tsuji N, Shioda T, Isselbacher KL, Takahashi H. Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Proc. Natl Acad. Sci. USA 1997; 94: 6420-5.
24. 24 Strand S, Hofmann WJ, Hug H et al. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumour cells: A mechanism of immune evasion? Nature Med. 1996; 2: 1361-6.
25. 25 Nagata S, Golstein P. The Fas death factor. Science 1995; 267: 1449-56.
26. 26 Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995; 270: 1189-92.
27. 27 Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC. A role for CD95 ligand in preventing graft rejection. Nature 1995; 377: 630-2.
28. 28 Miyawaki T, Uehara T, Nibu R et al. Differential expression of apoptosis-related Fas antigen on lymphocyte subpopulations in human peripheral blood. J. Immunol. 1992; 149: 3753-8.
29. 29 Cascino I, Fiucci G, Papoff G, Ruberti G. Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J. Immunol. 1995; 154: 2706-13.
30. 30 Caignard A, Guillard M, Cai Z, Asselin-Paturel C, Chouiab CS. The renal cell carcinoma specific lysis by a specific cytotoxic T cell clone is independent of the Fas/Fas-L cytotoxic pathway. Tissue Antigens 1996; 48: 295-300.
31. 31 Tanaka M, Suda T, Takahashi T, Nagata S. Expression of the functional soluble form of human Fas ligand in activated lymphocytes. EMBO J. 1995; 14: 1129-35.
32. 32 Iwai K, Miyawaki T, Takizawa T et al. Differential expression of bcl-2 and susceptibility of anti-Fas-mediated cell death in peripheral blood lymphocytes, monocytes, and neutrophils. Blood 1994; 84: 1201-8.
33. 33 Nunez G, Merino R, Grillot D, Gonzalez-Garcia M. Bcl-2 and Bcl-x: Regulatory switches for lymphoid death and survival. Immunol. Today 1994; 15: 582-8.
34. 34 Paraf F, Gogusev J, Chretien Y, Droz D. Expression of bcl-2 oncoprotein in renal cell tumours. J. Pathol. 1995; 177: 247-52.
35. 35 Tomita Y, Bilim V, Kawasaki T et al. Frequent expression of Bcl-2 in renal-cell carcinomas carrying wild-type p53. Int. J. Cancer 1996; 66: 322-5.
36. 36 Thoenes W, Storkel S, Rumpelt HJ. Histopathology and classification of renal cell tumors (adenomas, oncocytomas, carcinomas). The basic cytological and histopathological elements and their use for diagnostics. Pathol. Res. Pract. 1986; 181: 125-43.
37. 37 Chomezynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 1987; 162: 156-9.
38. 38 Olive C, Nicol D, Falk MC. Characterisation of γδ T cells in renal cell carcinoma patients by PCR analysis of T cell receptor transcripts. Cancer Immunol. Immunother. 1997; 44: 27-34.
39. 39 Weber-Nordt RM, Henschler R, Schott E et al. Interleukin-10 increases bcl-2 expression and survival in primary human CD34+ hematopoietic progenitor cells. Blood 1996; 88: 2549-58.
40. 40 Dhein J, Walczak H, Baumler C, Debatin KM, Krammer PH. Autocrine T-cell suicide mediated by APO-1/ (Fas/CD95). Nature 1995; 373: 438-41.
41. 41 Russell JH, Rush B, Weaver C, Wang R. Mature T cells of autoimmune lpr/lpr mice have a defect in antigen-stimulated suicide. Proc. Natl Acad. Sci. USA 1993; 90: 4409-13.
42. 42 Ercolani L, Florence B, Denaro M, Alexander M. Isolation and complete sequence of a functional human glyceraldehyde-3-phosphate dehydrogenase gene. J. Biol. Chem. 1988; 263: 15335-41.
43. 43 Nagata S, Suda T. Fas and Fas ligand: lpr and gld mutations. Immunol. Today 1995; 16: 39-43.
44. 44 Lau HT, Yu M, Fontana A, Stoeckert CJ. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science 1996; 273: 109-12.
45. 45 Seino K-I, Kayagaki N, Okumura K, Yagita H. Antitumor effect of locally produced CD95 ligand. Nature Med. 1997; 3: 165-70.
46. 46 Kang S-M, Schneider DB, Lin Z et al. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nature Med. 1997; 3: 738-43.
47. 47 Nonomura N, Miki T, Yokoyama M et al. Fas/APO-1-mediated apoptosis of human renal cell carcinoma. Biochem. Biophys. Res. Commun. 1996; 229: 945-51.
48. 48 Nakopoulou L, Stefanaki K, Papadakis J et al. Expression of bcl-2 oncoprotein in various types of glomerulonephritis and renal allografts. Nephrol. Dial. Transplant. 1996; 11: 997-1002.
49. 49 Takemura T, Murakami K, Miyazato H, Yagi K, Yoshioka K. Expression of Fas antigen and Bcl-2 in human glomeralonephritis. Kidney Int. 1995; 48: 1886-92.
50. 50 Hock H, Dorsch M, Kunzendorf U, Qin Z, Diamanstein I, Blankenstein T. Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon γ. Proc. Natl Acad. Sci. USA 1993; 90: 2774-8.
51. 51 James SY, Mackay AG, Colston KW. Effects of 1, 25 dihydroxy vitamin D3 and its analogues on induction of apoptosis in breast cancer cells. J. Steroid Biochem. Mol. Biol. 1996; 58: 395-401.
52. 52 Cotter FE, Johnson P, Hall P et al. Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model. Oncogene 1994; 9: 3049-55.